Inhibition of osteolytic lesions by SRC kinase inhibitors

Details Inhibition of osteolytic lesions by SRC kinase inhibitors Inhibition of osteolytic lesions by SRC kinase inhibitors

2006-06-16

2008-12-23

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07468379

ABSTRACT:
The present invention include methods and compositions for treating bone-resorbing diseases or bone resorption related to a pathologic condition generally, including, but not limited to osteoporosis, arthritis, rheumatoid arthritis, cancer metastases to the bone, bone cancer, hypercalcemia, osteolytic lesions with orthopedic implants, Paget's disease, and bone loss associated with hyperparathyroidism. Representative cancers include, but are not limited to breast cancer, prostrate cancer, colon cancer, endometrial cancer, multiple myeloma, renal cell carcinoma, heck and neck cancers, and cervical carcinoma. Arthritic conditions include, but are not limited to adjuvant-, collagen-, bacterial- and antigen-induced arthritis, particularly rheumatoid arthritis.

REFERENCES:
patent: 4870287 (1989-09-01), Cole et al.
patent: 5466468 (1995-11-01), Schneider et al.
patent: 5760395 (1998-06-01), Johnstone
patent: 6002008 (1999-12-01), Wissner et al.
patent: 2003/0212276 (2003-11-01), Boschelli et al.
patent: 2005/0101780 (2005-05-01), Boschelli et al.
Ammann et al., “Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency,”J. Clin. Invest., 99:1699-1703, 1997.
Blair et al., “Isolated osteoclasts resorb the organic and inorganic components of bone,”J. Cell Biol., 102:1164-1172, 1986.
Boschelli et al., “7-alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases,”J. Med. Chem., 47:1599-1601, 2004.
Boschelli et al., “Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity,”Bioorg. Med. Chem. Lett., 13:3797-3800, 2003.
Boschelli et al., “Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity,”J Med. Chem., 44:3965-77, 2001.
Boschelli et al., “Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles,”J Med. Chem., 44:822-833, 2001.
Bucay et al., “osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification,”Genes Dev., 12:1260-1268, 1998.
Franzoso et al., “Requirement for NF-κB in osteoclast and B-cell development,”Genes&Dev., 11:3482-3496, 1997.
International Search Report mailed Nov. 7, 2006, (PCT/US06/23529).
Iotsova et al., “Osteopetrosis in mice lacking NF-κB1 and NF-κB2,”Nat. Med., 3:1285-1289, 1997.
Johnson et al., “Pleiotropic effects of a null mutation in thec-fosproto-oncogene,”Cell, 71:577-586, 1992.
Kong et al., “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,”Nature, 397:315-323, 1999.
Lewis et al., “Osteoporosis induced in mice by overproduction of interleukin 4,”Proc. Natl. Acad. Sci. USA, 90:11618-11622, 1993.
Lomaga et al., “TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling,”Genes&Dev., 13:1015-1024, 1999.
Mizuno et al., “Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis,”Gene, 215:339-343, 1998.
Poli et al., “Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion ,”EMBO J., 13:1189-1196, 1994.
Soriano et al., “Targeted disruption of the c-srcproto-oncogene leads to osteopetrosis in mice,”Cell, 64:693-702, 1991.
Takahashi et al., “Overexpression of the granulocyte colony-stimulating factor gene leads to osteoporosis in mice,”Lab Invest, 74:827-34, 1996.
Ye et al., “Inhibition of Src kinase activity by 4-phenylamino-3-quinolinecarbonitriles: Optimization of the side chain at C-7,”221st National Meeting of the American Chemical Society, San Diego, Calif., Paper 145 (Poster), Apr. 2001.

Affiliated with

Also associated with

Rating

Inhibition of osteolytic lesions by SRC kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of osteolytic lesions by SRC kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of osteolytic lesions by SRC kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4048616